138 related articles for article (PubMed ID: 37929952)
1. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial.
Wang B; Zhou J; Wu X; Sun Y; Li L; Li P; Li M; Jiang W; Xu M; Feng B; Xu X; Cheng J; Xie W; Han T; Wang X; Li H; Piao H; Zhao X; Chen S; Meng T; Guan Q; Meng F; Kong Y; Ou X; Jia J; You H
Am J Gastroenterol; 2024 Apr; 119(4):700-711. PubMed ID: 37929952
[TBL] [Abstract][Full Text] [Related]
2. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C; Torres F; Sarin SK; Shah HA; Tripathi D; Brujats A; Rodrigues SG; Bhardwaj A; Azam Z; Hayes PC; Jindal A; Abid S; Alvarado E; Bosch J;
J Hepatol; 2022 Oct; 77(4):1014-1025. PubMed ID: 35661713
[TBL] [Abstract][Full Text] [Related]
4. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Jeng WJ; Chien RN; Chen YC; Lin CL; Wu CY; Liu YC; Peng CW; Su CW; Hsu CE; Liaw YF
Hepatology; 2024 Mar; 79(3):690-703. PubMed ID: 37625144
[TBL] [Abstract][Full Text] [Related]
6. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
Chang ML; Cheng JS; Chien RN; Liaw YF
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
[TBL] [Abstract][Full Text] [Related]
9. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.
Loglio A; Iavarone M; Grossi G; Viganò M; Rumi MG; Facchetti F; Lunghi G; Sangiovanni A; Colombo M; Lampertico P
Aliment Pharmacol Ther; 2018 Aug; 48(4):431-439. PubMed ID: 29920698
[TBL] [Abstract][Full Text] [Related]
11. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
Farina E; Loglio A; Tosetti G; Degasperi E; Viganò M; Gentile C; Monico S; Perbellini R; Borghi M; Facchetti F; Uceda Renteria SC; Ceriotti F; Cerini F; Primignani M; Lampertico P
Aliment Pharmacol Ther; 2023 Jun; 57(12):1407-1416. PubMed ID: 36978230
[TBL] [Abstract][Full Text] [Related]
12. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis.
Jeng WJ; Liaw YF
Semin Liver Dis; 2021 Aug; 41(3):349-357. PubMed ID: 34182587
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Zacharias AP; Jeyaraj R; Hobolth L; Bendtsen F; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD011510. PubMed ID: 30372514
[TBL] [Abstract][Full Text] [Related]
15. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
16. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis.
Lai Q; Mennini G; Giovanardi F; Rossi M; Giannini EG
Eur J Clin Invest; 2021 Aug; 51(8):e13575. PubMed ID: 33866547
[TBL] [Abstract][Full Text] [Related]
20. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
Qu J; Yu Z; Li Q; Chen Y; Xiang D; Tan L; Lei C; Bai W; Li H; Shang Q; Chen L; Hu X; Lu W; Li Z; Chen D; Wang X; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Chen G; Li Y; Zeng Z; Rong G; Dong Z; Chen Y; Lou M; Wang C; Lu Y; Zhang C; Yang Y
Trials; 2014 Nov; 15():438. PubMed ID: 25381721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
